Research Progress on Relationship between Oral Microbes and Digestive System Cancer

doi:10.13701/j.cnki.kqyxyj.2020.02.001

Abstract

Abstract: The human oral microbiota plays an important role in both human health and disease states. Over the past decade, the interaction between microbes and cancer has attracted much attention in understanding the various characteristics of complex microbial communities and the possible mechanisms by which microbiota participates in cancer prevention, carcinogenesis, and anticancer therapy. Numerous studies have shown that microbial disorders lead to cancer susceptibility through a variety of pathways. In this article, the effects of oral microbiota on digestive system cancers (including esophageal cancer, gastric cancer pancreatic cancer, and colorectal cancer) are reviewed to provide references for further research on the relationship between oral microbiota and digestive system cancers, as well as oral microbiota and systemic diseases and cancers.

Key words: oral microbiota, digestive system cancersConclusionesophageal cancerConclusiongastric cancerConclusionpancreatic cancerConclusioncolorectal cancer

ZHANG Zhimin, CHENG Boqun. Research Progress on Relationship between Oral Microbes and Digestive System Cancer[J]. Journal of Oral Science Research, 2020, 36(2): 93-97.

References

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136(5):E359-E386.
[2] Chen X, Winckler B, Lu M, et al. Oral microbiota and risk for esophageal squamous cell carcinoma in a high-risk area of China [J]. PLoS One, 2015, 10(12):e0143603.
[3] Lin EW, Karakasheva TA, Hicks PD, et al. The tumor microenvironment in esophageal cancer [J]. Oncogene, 2016, 35(41):5337-5349.
[4] Gao S, Li S, Ma Z, et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer [J]. Infect Agent Cancer, 2016, 11:3.
[5] Yuan X, Liu Y, Kong J, et al. Different frequencies of Porphyromonas gingivalis infection in cancers of the upper digestive tract [J]. Cancer Lett, 2017, 404:1-7.
[6] Peters BA, Wu J, Pei Z, et al. Oral microbiome composition reflects prospective risk for esophageal cancers [J]. Cancer Res, 2017, 77(23):6777-6787.
[7] Gao SG, Yang JQ, Ma ZK, et al. Preoperative serum immunoglobulin G and a antibodies to Porphyromonas gingivalis are potential serum biomarkers for the diagnosis and prognosis of esophageal squamous cell carcinoma [J]. BMC Cancer, 2018, 18(1):4-11.
[8] Meng F, Li R, Ma L, et al. Porphyromonas gingivalis promotes the motility of esophageal squamous cell carcinoma by activating NF-κB signaling pathway [J]. Microbes Infect, 2019, 21(7):296-304.
[9] Whitmore SE, Lamont RJ. Oral bacteria and cancer [J]. PLoS Pathog, 2014, 10(3):e1003933.
[10] Yamamura K, Baba Y, Nakagawa S, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis [J]. Clin Cancer Res, 2016, 22(22):5574-5581.
[11] Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk[J]. Clin Microbiol Rev, 2010, 23(4):713-739.
[12] El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion[J]. Gastroenterology, 1997, 113(1):15-24.
[13] Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis[J]. Gut, 2018, 67(6):1024-1032.
[14] Chen X, Wang A, Chu A, et al. Mucosa-associated microbiota in gastric cancer tissues compared with non-cancer tissues[J]. Front Microbiol, 2019,10:1261.
[15] Hu J, Han S, Chen Y, et al. Variations of tongue coating microbiota in patients with gastric cancer[J]. Biomed Res Int, 2015,2015:173729.
[16] Wu J, Xu S, Xiang C, et al. Tongue coating microbiota community and risk effect on gastric cancer[J]. J Cancer, 2018, 9(21):4039-4048.
[17] Sun J, Li X, Yin J, et al. A screening method for gastric cancer by oral microbiome detection[J]. Oncol Rep, 2018, 39(5):2217-2224.
[18] Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer [J]. Gastroenterology, 2013, 144(6):1252-1261.
[19] Farrell JJ, Zhang L, Zhou H, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer [J]. Gut, 2012, 61(4):582-588.
[20] Torres PJ, Fletcher EM, Gibbons SM, et al. Characterization of the salivary microbiome in patients with pancreatic cancer [J]. PeerJ, 2015, 3:e1373.
[21] Michaud DS, Izard J, Wilhelm-Benartzi CS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study [J]. Gut, 2013, 62(12):1764-1770.
[22] Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study [J]. Gut, 2018, 67(1):120-127.
[23] Zambirinis CP, Levie E, Nguy S, et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis [J]. J Exp Med, 2015, 212(12):2077-2094.
[24] Vaz J, Andersson R. Intervention on Toll-like receptors in pancreatic cancer [J]. World J Gastroenterol, 2014, 20(19):5808-5817.
[25] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J]. Int J Cancer, 2019, 144(8):1941-1953.
[26] Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer[J]. Nat Rev Cancer, 2017, 17(2):79-92.
[27] Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma [J]. Genome Res, 2012, 22(2):299-306.
[28] McCoy AN, Araújo-Pérez F, Azcárate-Peril A, et al. Fusobacterium is associated with colorectal adenomas [J]. PLoS One, 2013, 8(1):e53653.
[29] Mira-Pascual L, Cabrera-Rubio R, Ocon S, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers [J]. J Gastroenterol, 2015, 50(2):167-179.
[30] Yu T, Guo F, Yu Y. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy [J]. Cell, 2017, 170(3):548-563.
[31] Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer [J]. Science, 2017, 358(6369):1443-1448.
[32] Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin [J]. Cell Host Microbe, 2013, 14(2):195-206.
[33] Liu Y, Baba Y, Ishimoto T, et al. Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer [J]. J Gastroenterol, 2019, 54(1):33-41.
[34] Yu YN, Yu TC, Zhao HJ, et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment [J]. Oncotarget, 2015, 6(31):32013-32026.
[35] Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack [J]. Immunity, 2015, 42(2):344-355.